Showing results (141-150 of 188) with videos related to
Sort By:
Pageof 19
Leukemia & Lymphoma|September 4, 2023
Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemiaBhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, et al.American Journal of Hematology|March 15, 2020
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403Lawrence D Kaplan, Matthew J Maurer, Wendy Stock, et al.British Journal of Haematology|April 21, 2015
Jumping translocations, a novel finding in chronic lymphocytic leukaemiaCecelia R Miller, Deborah Stephens, Amy S Ruppert, et al.Oncotarget|April 17, 2017
The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemiaCecelia R Miller, Amy S Ruppert, Sydney Fobare, et al.American Journal of Hematology|July 24, 2015
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patientsDeborah M Stephens, Amy S Ruppert, William G Weirda, et al.Blood Advances|July 22, 2018
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)John C Byrd, Amy S Ruppert, Nyla A Heerema, et al.Blood|May 17, 2003
BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B StudyClaudia D Baldus, Stephan M Tanner, Amy S Ruppert, et al.The New England Journal of Medicine|May 3, 2008
MicroRNA expression in cytogenetically normal acute myeloid leukemiaGuido Marcucci, Michael D Radmacher, Kati Maharry, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemiaRainer Claus, David M Lucas, Stephan Stilgenbauer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic LeukemiaKerry A Rogers, Ying Huang, Amy S Ruppert, et al.Pageof 19